Literature DB >> 10869235

SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.

E R Martin1, E H Lai, J R Gilbert, A R Rogala, A J Afshari, J Riley, K L Finch, J F Stevens, K J Livak, B D Slotterbeck, S H Slifer, L L Warren, P M Conneally, D E Schmechel, I Purvis, M A Pericak-Vance, A D Roses, J M Vance.   

Abstract

There has been great interest in the prospects of using single-nucleotide polymorphisms (SNPs) in the search for complex disease genes, and several initiatives devoted to the identification and mapping of SNPs throughout the human genome are currently underway. However, actual data investigating the use of SNPs for identification of complex disease genes are scarce. To begin to look at issues surrounding the use of SNPs in complex disease studies, we have initiated a collaborative SNP mapping study around APOE, the well-established susceptibility gene for late-onset Alzheimer disease (AD). Sixty SNPs in a 1.5-Mb region surrounding APOE were genotyped in samples of unrelated cases of AD, in controls, and in families with AD. Standard tests were conducted to look for association of SNP alleles with AD, in cases and controls. We also used family-based association analyses, including recently developed methods to look for haplotype association. Evidence of association (P</=.05) was identified for 7 of 13 SNPs, including the APOE-4 polymorphism, spanning 40 kb on either side of APOE. As expected, very strong evidence for association with AD was seen for the APOE-4 polymorphism, as well as for two other SNPs that lie <16 kb from APOE. Haplotype analysis using family data increased significance over that seen in single-locus tests for some of the markers, and, for these data, improved localization of the gene. Our results demonstrate that associations can be detected at SNPs near a complex disease gene. We found that a high density of markers will be necessary in order to have a good chance of including SNPs with detectable levels of allelic association with the disease mutation, and statistical analysis based on haplotypes can provide additional information with respect to tests of significance and fine localization of complex disease genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869235      PMCID: PMC1287185          DOI: 10.1086/303003

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission.

Authors:  D Clayton
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

2.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.

Authors:  M A Pericak-Vance; J L Bebout; P C Gaskell; L H Yamaoka; W Y Hung; M J Alberts; A P Walker; R J Bartlett; C A Haynes; K A Welsh
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

3.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

4.  Analysis of association at single nucleotide polymorphisms in the APOE region.

Authors:  E R Martin; J R Gilbert; E H Lai; J Riley; A R Rogala; B D Slotterbeck; C A Sipe; J M Grubber; L L Warren; P M Conneally; A M Saunders; D E Schmechel; I Purvis; M A Pericak-Vance; A D Roses; J M Vance
Journal:  Genomics       Date:  2000-01-01       Impact factor: 5.736

5.  Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases.

Authors:  A M Saunders; K Schmader; J C Breitner; M D Benson; W T Brown; L Goldfarb; D Goldgaber; M G Manwaring; M H Szymanski; N McCown
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

6.  A comprehensive human linkage map with centimorgan density. Cooperative Human Linkage Center (CHLC).

Authors:  J C Murray; K H Buetow; J L Weber; S Ludwigsen; T Scherpbier-Heddema; F Manion; J Quillen; V C Sheffield; S Sunden; G M Duyk
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

7.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

Authors:  E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

9.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  93 in total

1.  Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease.

Authors:  D Fallin; A Cohen; L Essioux; I Chumakov; M Blumenfeld; D Cohen; N J Schork
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

2.  Efficient multipoint linkage analysis through reduction of inheritance space.

Authors:  K Markianos; M J Daly; L Kruglyak
Journal:  Am J Hum Genet       Date:  2001-03-14       Impact factor: 11.025

Review 3.  Genetic analysis of multiple sclerosis.

Authors:  Alastair Compston; Stephen Sawcer
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

4.  SNP genotyping on a genome-wide amplified DOP-PCR template.

Authors:  Struan F A Grant; Simone Steinlicht; Ulrike Nentwich; Rainer Kern; Barbara Burwinkel; Ralf Tolle
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

5.  Haplotype information and linkage disequilibrium mapping for single nucleotide polymorphisms.

Authors:  Xin Lu; Tianhua Niu; Jun S Liu
Journal:  Genome Res       Date:  2003-09       Impact factor: 9.043

6.  An efficient haplotyping method with DNA pools.

Authors:  Ester Inbar; Benjamin Yakir; Ariel Darvasi
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

7.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

8.  Long-range (17.7 kb) allele-specific polymerase chain reaction method for direct haplotyping of R117H and IVS-8 mutations of the cystic fibrosis transmembrane regulator gene.

Authors:  Genevieve Pont-Kingdon; Mohamed Jama; Christine Miller; Alison Millson; Elaine Lyon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

Review 9.  Autism: in search of susceptibility genes.

Authors:  Janine A Lamb; Jeremy R Parr; Anthony J Bailey; Anthony P Monaco
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

10.  A survey of haplotype variants at several disease candidate genes: the importance of rare variants for complex diseases.

Authors:  P-Y Liu; Y-Y Zhang; Y Lu; J-R Long; H Shen; Lan-J Zhao; F-H Xu; P Xiao; D-H Xiong; Y-J Liu; R R Recker; H-W Deng
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.